Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress

Inclusion Criteria: * Patients with ENT cancer of stage I to IVb that have to go under surgery and/or radiotherapy and/or chemotherapy as first line treatment. It may be a primary cancer or a new localisation. * Total score on HADS scale \>11 * Patients aged from 18 to 75 years * Signed informed consent * OMS \< 2, hospitalized or ambulatory * Are authorized to inclusion, psychoactive treatments at stable dosage for two weeks for benzodiazepins, neuroleptics, antihistaminics or other anxiolytics or hypnotics Exclusion Criteria: * Patients in palliative treatments * Previous bipolar disorder or schizophrenia * Major depressive episode with severity criteria * Suicidal patients * Acute infection * ASAT/ALAT \>3N * Creatinine clearance \<30 ml/mn * Natremia inferior to the laboratory standard * For alcoholic patients non abstinent at the time of inclusion, previous "delirium tremens" * Previous upper gist bleeding * Inefficacy or intolerance of previous treatment by escitalopram * Not compatible concomitant treatment: * Other antidepressive than escitalopram (except clonazepam) * all hypnotics (except zolpidem) * all anxiolytics (except clonazepam, clorazepate and diazepam) * medical treatment for smoking addiction like bupropion or varenicline * Pregnant or breastfeeding women * Patients under guardianship * Patients without insurance * Impossibility to follow the protocol for geographical, social or psychic reasons * Insufficient knowledge of French